Differences between baseline immunoglobulin levels and prognostic markers
| Variables . | IgA, n (%) . | IgG . | IgM, n (%) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Abnormal (n = 103) . | Normal (n = 406) . | P . | Abnormal (n = 139) . | Normal (n = 372) . | P . | Abnormal (n = 298) . | Normal (n = 212) . | P . | |
| Ratio of males to females | 1.5:1 | 1.8:1 | .457 | 1.5:1 | 1.8:1 | .562 | 1.8:1 | 1.6:1 | .585 |
| Median age (range), y | 70 (40-94) | 68 (34-99) | .081 | 68 (40-90) | 68 (34-99) | .58 | 68 (34-99) | 68 (44-93) | .646 |
| CLL Rai stage | <.001 | <.001 | .008 | ||||||
| 0 | 27 (26) | 174 (43) | 40 (29) | 162 (44) | 117 (39) | 85 (40) | |||
| I/II | 34 (33) | 95 (23) | 42 (30) | 87 (23) | 87 (29) | 42 (20) | |||
| III/IV | 15 (15) | 17 (4) | 19 (14) | 14 (4) | 24 (8) | 9 (4) | |||
| MBL | 6 (6) | 60 (15) | 15 (11) | 51 (14) | 32 (11) | 33 (16) | |||
| SLL | 21 (20) | 60 (15) | 23 (17) | 58 (16) | 38 (13) | 43 (20) | |||
| LDT, mo | .071 | .269 | .899 | ||||||
| >12 | 77 (75) | 331 (82) | 106 (76) | 303 (81) | 237 (80) | 33 (16) | |||
| 6-12 | 12 (12) | 44 (11) | 17 (12) | 40 (11) | 32 (11) | 44 (21) | |||
| <6 | 12 (12) | 22 (5) | 13 (9) | 21 (6) | 21 (7) | 22 (10) | |||
| ZAP-70 positive/ZAP-70 negative | 31/49 (30/48) | 92/245 (23/60) | .06 | 35/78 (25/56) | 88/218 (24/59) | .748 | 74/177 (25/59) | 49/118 (23/56) | 1 |
| CD38 positive/CD38 negative | 39/47 (38/46) | 84/260 (21/64) | <.001 | 41/76 (30/55) | 82/233 (22/63) | .085 | 83/174 (28/58) | 39/135 (18/64) | .034 |
| B2M | .005 | .169 | .723 | ||||||
| High | 55 (53) | 141 (35) | 65 (47) | 131 (35) | 115 (39) | 81 (38) | |||
| Normal | 21 (20) | 124 (31) | 37 (27) | 108 (29) | 89 (30) | 56 (26) | |||
| IGHV mutated/unmutated | 38/36 (37/35) | 168/112 (41/28) | .227 | 56/47 (40/34) | 150/103 (40/28) | .463 | 138/78 (46/26) | 67/72 (32/34) | .005 |
| Variables . | IgA, n (%) . | IgG . | IgM, n (%) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Abnormal (n = 103) . | Normal (n = 406) . | P . | Abnormal (n = 139) . | Normal (n = 372) . | P . | Abnormal (n = 298) . | Normal (n = 212) . | P . | |
| Ratio of males to females | 1.5:1 | 1.8:1 | .457 | 1.5:1 | 1.8:1 | .562 | 1.8:1 | 1.6:1 | .585 |
| Median age (range), y | 70 (40-94) | 68 (34-99) | .081 | 68 (40-90) | 68 (34-99) | .58 | 68 (34-99) | 68 (44-93) | .646 |
| CLL Rai stage | <.001 | <.001 | .008 | ||||||
| 0 | 27 (26) | 174 (43) | 40 (29) | 162 (44) | 117 (39) | 85 (40) | |||
| I/II | 34 (33) | 95 (23) | 42 (30) | 87 (23) | 87 (29) | 42 (20) | |||
| III/IV | 15 (15) | 17 (4) | 19 (14) | 14 (4) | 24 (8) | 9 (4) | |||
| MBL | 6 (6) | 60 (15) | 15 (11) | 51 (14) | 32 (11) | 33 (16) | |||
| SLL | 21 (20) | 60 (15) | 23 (17) | 58 (16) | 38 (13) | 43 (20) | |||
| LDT, mo | .071 | .269 | .899 | ||||||
| >12 | 77 (75) | 331 (82) | 106 (76) | 303 (81) | 237 (80) | 33 (16) | |||
| 6-12 | 12 (12) | 44 (11) | 17 (12) | 40 (11) | 32 (11) | 44 (21) | |||
| <6 | 12 (12) | 22 (5) | 13 (9) | 21 (6) | 21 (7) | 22 (10) | |||
| ZAP-70 positive/ZAP-70 negative | 31/49 (30/48) | 92/245 (23/60) | .06 | 35/78 (25/56) | 88/218 (24/59) | .748 | 74/177 (25/59) | 49/118 (23/56) | 1 |
| CD38 positive/CD38 negative | 39/47 (38/46) | 84/260 (21/64) | <.001 | 41/76 (30/55) | 82/233 (22/63) | .085 | 83/174 (28/58) | 39/135 (18/64) | .034 |
| B2M | .005 | .169 | .723 | ||||||
| High | 55 (53) | 141 (35) | 65 (47) | 131 (35) | 115 (39) | 81 (38) | |||
| Normal | 21 (20) | 124 (31) | 37 (27) | 108 (29) | 89 (30) | 56 (26) | |||
| IGHV mutated/unmutated | 38/36 (37/35) | 168/112 (41/28) | .227 | 56/47 (40/34) | 150/103 (40/28) | .463 | 138/78 (46/26) | 67/72 (32/34) | .005 |
All data are n (%) of cases where data available, unless otherwise indicated. Abnormal immunoglobulins include patients with both high and low levels.